Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid

In Vivo

Volumn 25, Issue 3, 2011, Pages 325-333

  Schmidt, Matthias ^a   Kim, Young ^a   Gast, Sanna Marie ^a   Endo, Tomoyuki ^b,c   Lu, Desheng ^b   Carson, Dennis ^b   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Beta catenin; Lenalidomide; Lymphoma; Myeloma; Signal transduction; Wnt pathway

Indexed keywords

BETA CATENIN; BORTEZOMIB; DOXORUBICIN; ETACRYNIC ACID; LENALIDOMIDE; RITUXIMAB; THALIDOMIDE; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL VIABILITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL LINE; MYELOMA; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 79956359593     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cadigan KM and Liu YI: Wnt signaling: complexity at the surface. J Cell Sci 119: 395-402, 2006.
2. 2+ pathways. Oncogene 18: 7860-7872, 1999. (Pubitemid 30066232)
3. You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, MacDougald OA, Brown AM, Evan G, Kitajewski J and Wang CY: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol 157: 429-440, 2002. (Pubitemid 34839807)
4. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
5. Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701, 2004. (Pubitemid 39150127)
6. Nusse R: Wnt signaling in disease and in development. Cell Res 15: 28-32, 2005.
7. Polakis P: Wnt signaling and cancer. Genes Dev 14: 1837-1851, 2000.
8. Willert K and Jones KA: Wnt signaling: Is the party in the nucleus? Genes Dev 20: 1394-1404, 2006.
9. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, Kipps TJ, Corr M and Carson DA: Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci 101: 3118-3123, 2004. (Pubitemid 38327744)
10. Aizawa S, Ookawa K, Kudo T, Asano J, Hayakari M, Tsuchida S. Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci 94: 886-893, 2002.
11. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug-resistant and -sensitive cell lines. Cancer Res 48: 3622-3625, 1988.
12. Estrela JM, Ortega A and Obrador E: Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43(2): 143-181, 2006.
13. McCaughan FM, Brown AL and Harrison DJ: The effect of inhibition of glutathione-S-transferase P on the growth of the Jurkat human T-cell line. J Pathol 172: 357-362, 1994. (Pubitemid 24168653)
14. Nagourney RA, Messenger JC, Kern DH and Weisenthal LM: Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues. Cancer Chemother Pharmacol 26: 318-322, 1990. (Pubitemid 20271532)
15. Hoffman BD, Hanauske-Abel HM, Flint A and Lalande M: A new class of reversible cell cycle inhibitors. Cytometry 12: 26-32, 1991.
16. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IGH, Kipps TJ and Carson DA: Ethacrynic acid exhibitis selective cytotoxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PloS one 4(12): e8294, 2009.
17. Schmidt M, Sievers E, Endo T, Lu D, Cason D and Schmidt-Wolf IGH: Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 144(5): 796-798, 2009.
18. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B and Shaughnessy JD Jr.: The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109: 4470-4477, 2007. (Pubitemid 46743417)
19. Knobloch J and Rüther U: Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7: 1121-1127, 2008. (Pubitemid 351749260)
20. Kim Y, Alpmann P, Blaum-Feder S, Kraemer S, Endo T, Lu D, Carson D and Schmidt-Wolf IGH: In vivo efficacy of griseofulvin against multiple myeloma. Leuk Res Nov 26, 2010. Epub ahead of print.
21. Kim Y, Alpmann P, Blaum-Feder S, Kraemer S, Endo T, Lu D, Carson D and Schmidt-Wolf IGH: Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 25(1): 99-103, 2011.
22. Sukhdeo K, Mani M, Zhang Y et al: Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104(18): 7516-7521, 2007. (Pubitemid 47185938)